Physician profile
Vanessa Heller
NPI 1831993815
$809.13
in general payments reported to CMS, 2019-2025
13 companies · $809 in 2025
The $809 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.59 | 2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $121.14 | 2025 | Auvelity |
| Pfizer INC. | $89.60 | 2025 | |
| Abbvie INC. | $84.51 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $49.84 | 2025 | |
| Esperion Therapeutics, INC. | $43.13 | 2025 | Nexletol |
| Tonix Medicines, INC. | $41.81 | 2025 | Zembrace Symtouch |
| Exact Sciences Corporation | $34.89 | 2025 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $25.34 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.03 | 2025 | Jardiance |
| Ardelyx, INC. | $23.75 | 2025 | Ibsrela |
| Amgen INC. | $23.35 | 2025 | Repatha |
| Scilex Pharmaceuticals INC. | $16.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.